Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal bupivacaine versus standard bupivacaine for femoral nerve block in total knee arthroplasty
ChiCTR2300077551Phase 4Not yet recruiting
- Sponsor
- First People's Hospital of Lianyungang City
- Start
- Nov 2023
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of liposomal bupivacaine and bupivacaine in postoperative pain (3 arms), sponsored by First People's Hospital of Lianyungang City. Primary endpoint: NRS score 24 hours after surgery. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
liposomal bupivacainebupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on ChiCTR2300077551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077551.